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Objective - To assess the impact of syncope during
sustained ventricular tachycardia on total and cardiac
mortality in patients with chronic chagasic heart disease.
Methods - We assessed 78 patients with sustained
ventricular tachycardia and chronic Chagas'  heart
disease. The mean age was 53±10 years, 45 were males,
and the mean ejection fraction was 49.6±13%. The
patients were divided into 2 groups according to the pre-
sence (GI=45) or absence (GII=33) of syncope during sus-
tained ventricular tachycardia.
Results - After a mean follow-up of 49 months, total
mortality was 35% (28 deaths), 22 deaths having a cardiac
cause (78.6%). No difference was observed in total (33.3% x
39.4%) and cardiac (26.7% x 30.3%) mortality, or in
nonfatal sustained ventricular tachycardia between GI and
GII patients (57.6% x 54.4%, respectively). However, the
presence of syncope during recurrences was significantly
greater in those patients who had had the symptom from the
beginning (65.4% x 18.1%, p<0.01).
Conclusion - Syncope during the presentation of
sustained ventricular tachycardia is not associated with
an increase in total or cardiac mortality in patients with
chronic Chagas' heart disease. However, syncope during
the recurrence ventricular tachycardia is greater in pati-
ents experiencing syncope in the first episode, of sustained
ventricular tachycardia.
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Identification of patients at high risk of cardiac death is
fundamental in cardiological investigation. The importance
of syncope during the clinical presentation of sustained ven-
tricular tachycardia, as a prognostic factor, was extensively
studied in patients with coronary artery disease, and it was
considered a worse prognosis when compared with hemo-
dynamically well-tolerated sustained tachyarrhythmias 1-5. In
chronic chagasic heart disease, however, the relevance of
syncope during clinical presentation of sustained ventricu-
lar tachycardia is not totally understood, and its incidence is
variable according to reports published in the literature 6-10.
The objective of this study was to assess the impact of
syncope during the clinical presentation of sustained ven-
tricular tachycardia on total, cardiac, and sudden death in
patients with chronic chagasic heart disease.
Methods
We consecutively assessed 78 patients with chronic
Chagas' heart disease after an episode of sustained ventri-
cular tachycardia in the clinical electrophysiology section of
the Hospital São Paulo of the Universidade Federal de São
Paulo. Forty-five patients were males and 33 were females,
their mean age being 53±10 years (29 to 74). The mean left
ventricular ejection fraction was 49.6% ± 13% (24 to 76), and
24 (30.8%) patients had ejection fraction < 40%. In this po-
pulation, 11.5% of the patients had advanced heart failure
(NYHA functional class III or IV).
All patients had their diagnosis of Chagas’ disease
confirmed by serological tests, and the presence of heart di-
sease was confirmed by alterations on the 12-lead electrocar-
diogram, chest radiography, ambulatory electrocardiogra-
phic monitoring (Holter), echocardiogram, radionuclide ven-
triculography, and left ventricular angiography. Monomor-
phic spontaneous sustained ventricular tachycardia was re-
corded on an electrocardiogram or on Holter monitoring in all
patients. Coronary angiography was performed in all males
older than 35 years and in all females older than 40 years.
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The electrophysiological study with programmed ven-
tricular stimulation was performed in all patients, according
to stimulation techniques previously reported 10-13, using up
to 3 extrastimuli with a minimum coupling of 200ms, under 2
cycles of basal stimulation (600 and 450ms) 10-13.
The patients were classified according to the presence
(group I) or absence (group II) of syncope during clinical
presentation of sustained ventricular tachycardia.
To comply with the objectives of the study, the follo-
wing definitions were used: 1) syncope, the sudden loss of
consciousness followed by spontaneous recovery, conside-
red present when the episode occurred during electrocar-
diographic monitoring or when, after regaining conscious-
ness, the patient was in sustained ventricular tachycardia; 2)
sustained ventricular tachycardia, which is the presence of
consecutive ventricular beats with a heart rate >100bpm and
duration >30s, or the need for immediate reversion, when he-
modynamic impairment occurs; 3) sudden cardiac death, in
the case of a witnessed death, occurring within 1 hour at most
after symptom onset in a clinically stable patient, or in the case
of an unwitnessed death, the patient should have been
asymptomatic within the 24 hours preceding death; 4) car-
diac death, the sum of sudden death and that resulting from-
 progression of heart failure or thromboembolic events; 5)
recurrence of nonfatal sustained ventricular tachycardia, re-
corded on an electrocardiogram or Holter, with no evolution
to ventricular fibrillation or cardiopulmonary arrest.
After hospital discharge, the patients were assessed
monthly during the first 6 months, and then bimonthly du-
ring the first year. During follow-up, the following events
were defined: death due to cardiac causes (sudden and
nonsudden), to noncardiac causes, deaths after a maximum
follow-up of 10 years, and recurrence of nonfatal sustained
ventricular tachycardia. The initial treatment was conside-
red the one used since hospital discharge, and maintenance
treatment comprised the drugs used since the last contact.
Continuous variables were presented as mean ± standard
deviation. For comparison between the groups, the chi-square
test or Fisher exact test, when appropriate, was used for
qualitative variables, and Student t test was used for quan-
titative variables. Survival curves were depicted according to
the Kaplan-Meier method and compared by the log-rank test.
Results
Of the 78 patients, 45 (57.7%) experienced syncope
during clinical presentation of sustained ventricular tachy-
cardia and comprised group I; the 33 (42.3%) patients who
did not experience syncope comprised group II. Other
symptoms present during sustained ventricular tachycar-
dia were palpitation in 67 patients (GI=39 and GII=28,
p=0.50) and dyspnea in 38 patients (GI=21 and GII=17,
p=0.40). The clinical characteristics of both groups are sho-
wn in table I. No difference between group I and II patients
was observed in regard to age (52.5±10 and 53.2±10,
p=0.31), sex, presence of advanced heart failure, left ventri-
cular ejection fraction (48.1±13 and 51.6±13, p=0.8), number
of patients with ejection fraction <40% [GI=16 (35.6%) and
GII=8 (24.2%), (p=0.21)], and segmentary alteration (77.8%
and 69.7%, p=0.29). Density of isolated ventricular extrasys-
toles per hour (193 vs 91, p=0.04) and nonsustained ventri-
cular tachycardia in 24 hours (70 vs 8, p=0.25) recorded on
the initial Holter was greater in the patients with syncope.
Most patients had electrocardiographic alterations,
which were present in 80% (n=36) of the patients with
syncope and 78.8% (n=26) of those without. The most com-
mon electrocardiographic findings were as follows: right
bundle-branch block associated with left anterosuperior di-
visional block (29.5%), isolated right bundle-branch block
(10.3%), isolated left bundle-branch block (10.3%), and left
divisional anterosuperior block (11.5%). None of these alte-
rations predominated in the patients experiencing or not ex-
periencing syncope.
The frequency cycle of clinical sustained ventricular
tachycardia was analyzed in 49 patients (GI=25, GII=24). The
mean frequency cycle in GI was 314 ms [95% CI 282-347],
and, in GII, it was 309 ms [95% CI 282-337], with no statisti-
cally significant difference between the groups (p=0.79).
During electrophysiological study with programmed
ventricular stimulation, sustained ventricular tachycardia
was induced in 75 patients. The frequency cycle of induced
sustained ventricular tachycardia was 296 ms [95% CI 273-
319] in the patients experiencing syncope and 325 ms [95%
CI 299-351] in those not experiencing syncope (tab. I). A ten-
dency toward a shorter frequency cycle of induced sustai-
ned ventricular tachycardia was observed in the patients
experiencing syncope (p=0.08).
All chagasic patients with sustained ventricular ta-
chycardia were successfully treated and were available for
ambulatory follow-up. The cardiac drugs used during the
last contact are listed in table II. At the end of follow-up, 71
patients were using amiodarone, 41 (91.1%) in the group of
Table I – Baseline characteristics of patients with sustained ventricular
tachycardia and chronic chagasic heart disease according to the
presence of syncope during clinical presentation of the arrhythmia
Group I Group II
with syncope   without syncope
(N=45) (N=33) P
Age (years) 52.5±10 53.2±10 0.31
Male sex (%) 29 (54.4) 16 (48.5) 0.12
Abnormal ECG (%) 36 (80) 26 (78.8) 0.91
Segmentary alteration (%) 35 (77.8) 23 (69.7) 0.29
Ejection fraction 48.0 ±13 51.6±13 0.79
Ejection fraction <40% (%) 16 (35.6) 8 (24.2) 0.21
NYHA Functional
class III and IV (%) 13.3% 9.1% 0.41
Frequency cycle 314±78 309±65 0.79
of clinical SVT (ms)
Frequency cycle 296±78 325±71 0.08
of induced SVT (ms)
Isolated VE/h 193 91 0.04*
NSVT/24h 70 8 0.25
Follow-up duration (months) 47±27 42±25 0.80
ECG- electrocardiogram; SVT- sustained ventricular tachycardia; VE-
ventricular extrasystoles; NSVT- nonsustained ventricular tachycardia.
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in group II, the mean follow-up was 46±32 months, and 5
(15.1%) patients were followed up for less than 24 months.
Total mortality was 35% (28 deaths). No difference
between the groups was observed in regard to total morta-
lity; 15 (33.3%) patients died in group I, and 13 (39.4%) pati-
ents died in group II (tab. III). The survival curve showed
that, during the entire clinical follow-up, total mortality was
similar in both groups (fig. 2).
Of the deaths in the 78 patients, 28.2% had cardiac
causes, accounting for 78.6% of deaths in this population
(22 deaths). Figure 3 shows the curve of accumulated car-
diac deaths in the 78 patients, which did not statistically dif-
fer between groups I and II (p=0.64), 12 (26.7%) and 10
(30.3%) being the deaths from cardiac causes, respectively.
Most cardiac deaths occurred suddenly. Of all cardiac dea-
ths, 63.6% were considered sudden (14 deaths). Sudden
death accounted for 50% (6/12) of the cardiac deaths in
group I patients and for 80% (8/10) of the deaths in group II
patients (p=0.24). Mean survival in group I was 83 months
[95% CI 70-97], and in group II it was 75 months [95% CI 59-
92] (tab. III).
Recurrence of nonfatal sustained ventricular tachycar-
dia was observed in 44 (56.4%) patients, 26 being in group I
(57.8%) and 18 in group II (54.5%). No difference between
the 2 groups was observed in the recurrence of nonfatal
sustained ventricular tachycardia (fig. 4). Recurrences of
sustained ventricular tachycardia were accompanied by
syncope in 26.9% of the patients, being more frequent in
those who already had the symptom prior to antiarrhythmic
patients experiencing syncope and 30 (90.9%) in those not
experiencing syncope (p=0.21). Six patients were using
sotalol, and 2 patients were not using antiarrhythmic drugs.
Catheter ablation was performed in 34 patients, 18 (40%) pa-
tients in group I and 16 (45%) patients in group II (p=0.50).
The use of a definitive pacemaker for bradyarrhythmias did
not differ in the 2 groups. Six (13.3%) patients experiencing
syncope and 7 (21.2%) not experiencing syncope used pa-
cemakers implanted for bradyarrhythmias.
The mean follow-up time (fig. 1) was 49±33 months,
and all patients were followed up for at least 1 year, except 1
patient in GI who was followed up for 10 months. In group I,
the mean follow-up was 51±32 months, and 7 (15.5%) pati-
ents in this group were followed up for less than 24 months;
Table II – Pharmacological and antiarrhythmic treatment
Group I Group II P
 with syncope without syncope
N=(45) N=(33)
Digitalis 10 (22.2%) 7 (21.2%) 1.00
ACE I 28 (62.2%) 24 (72.7%) 0.46
Diuretics 15 (33.3%) 17 (51.5%) 0.16
Amiodarone 41 (91.1%) 390.2±73.5 0.21
Dose média (mg) 30 (90.9%) 386.6±68.1 0.83
Sotalol 5 (15.1%) 1 (3%) 0.31
mean dose (mg) 224±35 160
Catheter ablation 18 (40%) 16 (45%) 0.50
Definitive pacemaker 6 (13.3%) 7 (21.2%) 0.75
ACE I - angiotensin-converting enzyme inhibitors.
Fig. 1 – Events during clinical follow-up of patients with chronic chagasic heart disease according to the presence of syncope during clinical presentation of sustained ventricular
tachycardia. TM- total mortality; CM- cardiac mortality; SCM- sudden cardiac mortality.
TM CM SCM TM CM SCM
With Syncope Without Syncope
SVT recurrence 26 SVT recurrence 18
Syncope during recurrence Syncope during recurrence
SVT + Chagas' Disease
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therapy. In the 26 group I patients with recurrence of
nonfatal sustained ventricular tachycardia, 17 (65.4%) expe-
rienced syncope; in the 18 group II patients with recurrence
of nonfatal sustained ventricular tachycardia, 4 (22.2%)
experienced syncope (p<0.01).
To assess the importance of syncope associated with
sustained ventricular tachycardia, the patients experien-
cing syncope at any time during the study were compared
with those not experiencing it. Therefore, syncope associa-
ted with sustained ventricular tachycardia occurred in 4 of
the 33 patients whose arrhythmia had initially occurred wi-
thout syncope, adding to the 49 patients who experienced
syncope associated with sustained ventricular tachycardia
at any time during the study. When these 49 patients with
syncope associated with sustained ventricular tachycardia
were compared with the 29 without syncope, total (36.7%
vs. 34.5%, p=0.91) and cardiac (24.5% and 34.5%) mortality
did not differ at any time during the study.
Total and cardiac mortality was greater in the patients
with left ventricular ejection fraction lower than 40%. Of the
28 deaths occurring during total clinical follow-up, 50% of
the patients had an ejection fraction lower than 40% as
compared with 30.8% of the total population and 29% of the
patients without this event; this difference, however, was
not statistically significant.
Discussion
Our study assessed the impact of syncope during the
Table III – Total, cardiac, and sudden mortality, and recurrence of nonfatal sustained ventricular tachycardia in patients with chronic chagasic
heart disease
Total Cardiac Sudden SVT Survival Recurrence -free
Mortality mortality mortality recurrence (m) time (m)
(N=28) (N=22) (N=14) [95% CI] [95% CI]
Group I – with 15 (33.3%) 12 (26.7%) 6 (50%) 26 (57.8%) 83 [70; 97] 71 [59; 83]
 syncope (N=45)
Group II – without 13 (39.4%) 10 (30.3%) 8 (80%) 18 (54.5%) 75 [59; 92] 64 [50; 78]
syncope (N=33)
P 0.43 0.59 0.24 0.82 0.50 0.59
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Group II
Fig. 2 – Total survival curve of patients with chronic chagasic heart disease and sus-
tained ventricular tachycardia according to the presence of syncope during clinical
presentation of the arrhythmia. Group I- with syncope; group II- without syncope.
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p = 0,59
Fig. 3 – Curve of accumulated cardiac mortality in patients with chronic chagasic
heart disease and sustained ventricular tachycardia according to the presence of
syncope during clinical presentation of the arrhythmia. Group I- with syncope;
group II- without syncope.
Months
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Fig. 4 – Recurrence-free survival of nonfatal sustained ventricular tachycardia in pa-
tients with chronic chagasic heart disease and sustained ventricular tachycardia ac-
cording to the presence of syncope during clinical presentation of the arrhythmia.
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p = 0,82
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clinical presentation of sustained ventricular tachycardia on
total and cardiac mortality in patients with chronic chagasic
heart disease. In our case series, the presence of syncope
during sustained ventricular tachycardia, even though
frequent (57.7%), did not influence total and cardiac
mortality in the long run.
Sustained ventricular tachycardia in patients with
structural heart disease is a potentially lethal arrhythmia.
Previous studies reported that, in the presence of structural
cardiac impairment, mainly in ischemic heart disease, when
sustained ventricular tachycardia is accompanied by syn-
cope or cardiopulmonary arrest, the risk of a fatal recurrence
is greater than when this arrhythmia is hemodynamically
well tolerated 1-5. In chronic chagasic heart disease, howe-
ver, the impact of the presence of syncope during clinical
presentation of sustained ventricular tachycardia has been
studied less 6-14.
Scanavacca et al 9, studied 35 patients with sustained
ventricular tachycardia and chronic chagasic heart disease
treated with amiodarone. They showed that, despite recur-
rence of arrhythmia in 30% of the patients, no death was
observed in patients with an ejection fraction >30% and
who were in functional class I or II during 27 months of cli-
nical follow-up. In their study, cardiac mortality was 11.4%,
occurring in patients with severe ventricular dysfunction.
However, the authors did not evaluate mortality according to
the clinical presentation of the arrhythmia. Mendoza et al 15
reported a mortality rate of 20% in patients with sustained
ventricular tachycardia and chronic chagasic heart disease;
however the importance of clinical presentation during the
spontaneous arrhythmia in the evolution of these patients
was not mentioned. In our study, total (33.3% vs. 39.4%,
p=0.43) and cardiac (26.7% vs. 30.3%, p=0.59) mortality was
similar in patients with and without syncope. These results
may not be attributed to differences in clinical, electrophy-
siological, or therapeutical characteristics, because they
were similar for both groups, and most patients were recei-
ving amiodarone. The higher mortality rate in our study as
compared with that in other studies may have been due to
the larger size of our sample and our longer follow-up.
It is important to emphasize that when we analyzed only
the patients with ejection fraction below 40%, total, cardiac,
and sudden deaths were similar in the patients with and
without syncope. However, contrary to that which happens
in coronary artery disease, but similar to that reported in other
studies involving only patients with Chagas’ disease 6,15-18,
sustained ventricular tachycardia occurred in patients with
mild ventricular dysfunction, as shown by the mean ejection
fraction of 49.6%, and in only 30.8% of the patients with
ejection fraction below 40%. Bestetti et al 6 reported ventricu-
lar dysfunction in 50% of the chagasic patients with sus-
tained ventricular tachycardia studied with echocardio-
graphy; only 10% had severe dysfunction. In patients un-
dergoing catheter ablation, Sosa et al 16 reported a mean ejec-
tion fraction of 62%, measured on echocardiography; these
results were similar to those reported by Mendoza et al 15,
studying 15 chagasic patients with sustained ventricular
tachycardia (mean ejection fraction of 56%). The small
number of patients with severe ventricular dysfunction in our
population was certainly a limitation in evaluating the
importance of syncope associated with sustained ventricular
tachycardia when the ejection fraction was reduced.
In our study, we could also observe a similar recur-
rence rate of sustained ventricular tachycardia in patients
with and without syncope (57.8% vs. 54.5%, p=0.82);
syncopal sustained ventricular tachycardia, however, was
more frequent in patients who had the symptom from the be-
ginning [17/26 (65.4%) vs. 4/18 (22%), p<0.01]. Our data
suggest that the presence of syncope during sustained
ventricular tachycardia does not increase the probability of
recurrence. Patients with previous episodes of syncope,
however, more commonly experience this symptom during
recurrences of sustained ventricular tachycardia. Likewise,
Scanavacca et al 9 reported a 56% probability of recurrence
of sustained ventricular tachycardia in 36 months, which
was similar for patients with and without syncope or resus-
citated sudden death at the beginning of the study. No refe-
rence to the presence or absence of syncope associated
with recurrences was made in their study results.
Syncope in chronic chagasic heart disease may result
from 3 factors: tachyarrhythmias, bradyarrhythmias, and
autonomic dysfunction. Syncope associated with sustai-
ned ventricular tachycardia has a variable incidence repor-
ted in the literature 6-10. In the study by Bestetti et al 6, 3 out
of 15 chagasic patients with sustained ventricular tachycar-
dia had syncope, but only 1 during arrhythmia. Scanavacca
et al 9, in a similar population, reported syncope in 37% of the
35 patients studied. In patients with sustained ventricular
tachycardia and chronic chagasic heart disease, who had
undergone epicardial ablation, Sosa et al 16 reported a 60%
incidence of syncope and presyncope. This result was simi-
lar to the 62.5% incidence reported by de Paola et al 10 in
chagasic patients with sustained ventricular tachycardia
undergoing angiographic and electrophysiological studies,
and to the 58% found in our study.
Even though syncope has been studied in the context
of chronic chagasic heart disease, specifically during the cli-
nical presentation of sustained ventricular tachycardia, its
importance as a prognostic determinant is not totally kno-
wn. Martinelli et al 13 carried out an electrophysiological
study in 53 chagasic patients with recurring syncope and
reported that mortality was significantly greater in the pati-
ents who had induced sustained ventricular tachycardia du-
ring programmed ventricular stimulation. Mendonça et al 14
showed that inducibility of sustained ventricular tachycar-
dia was greater in patients with nonsustained ventricular ta-
chycardia and syncope, who evolved with cardiac death
(45.4% x 14.2%, p<0.05). In these studies, however, no refe-
rence was made to the presence of syncope associated with
spontaneous sustained ventricular tachycardia. Bestetti et
al 6, studying 74 patients with chagasic heart disease, repor-
ted that syncope was not a predictor of sudden death in
this population. The authors did not include exclusively
patients with sustained ventricular tachycardia, and, there-
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The hemodynamic response to sustained ventricular
tachycardia depends on several factors, which include ven-
tricular dysfunction, atrioventricular synchronism, the fre-
quency cycle of ventricular tachycardia, and the response
of the autonomous nervous system 19-20. However, the
response of blood pressure and severity of the symptoms
may vary even in patients with similar ventricular function
and ventricular tachycardia frequency cycles 19-23.
The frequency cycle of sustained ventricular tachy-
cardia has been valued as 1 of the major markers of the hemo-
dynamic response to ventricular tachycardia. Adhar et al 21
reported that the frequency cycle of ventricular tachycardia
induced by electrophysiological study was shorter when
clinical ventricular tachycardia manifested with syncope.
However, this difference did not persist after multivariate
analysis. On the other hand, Landolina et al 22 showed that
hemodynamic deterioration resulted from impaired barore-
flex sensitivity, and not from the ejection fraction and the
frequency cycle of tachycardia. In our study, the frequency
cycle of clinical sustained ventricular tachycardia of the pa-
tients with syncope (314 ms, 95% CI 282-347) did not signi-
ficantly differ from that observed in patients without synco-
pe (309 ms, 95% CI 282-337). However, a tendency (0.08) to-
wards a shorter frequency cycle of induced sustained ventri-
cular tachycardia was observed in patients in group I [296 ms
(95% CI 273-319)] as compared with those in group II [325 ms
(95% CI 299-351)]. Therefore, the presence of syncope in
group I patients cannot be explained by the difference in the
frequency cycle of sustained ventricular tachycardia.
Recently, Landolina et al 22 and Hamdan et al 23 repor-
ted that impaired baroreflex sensitivity correlated with he-
modynamic deterioration during sustained ventricular ta-
chycardia, and that the gain in arterial baroreflex significan-
tly contributed to hemodynamic stability after initial dete-
rioration. These studies were carried out in patients with
coronary artery disease, in which severe impairment of the
autonomous nervous system is an important prognostic
factor, because it denotes an advanced stage of heart fai-
lure, the major predictor of mortality. Chagas’ disease may
affect the autonomous nervous system, independently
from advanced cardiac impairment, or without advanced
heart failure, and this may partially explain the mechanism of
syncope in these patients, without resulting in an increase
in mortality. However, because in our study no assessment
of the autonomous nervous system was performed, no con-
clusion can be drawn in regard to its role in the occurrence
of syncope in this population.
In conclusion, our data suggest that the presence of
syncope during sustained ventricular tachycardia did not
influence total, cardiac, or sudden mortality in the chagasic
population treated with amiodarone, despite the high recur-
rence rate of the arrhythmia. In addition, the probability of
occurrence of syncope during the recurrence of sustained
ventricular tachycardia was greater in the patients who had
previously experienced the symptom. Until more specific
predictors of risk are identified, the management of chagasic
patients who have sustained ventricular tachycardia should
not be influenced by the presence of syncope during the
clinical presentation of the arrhythmia.
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